

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 April 2004 (22.04.2004)

PCT

(10) International Publication Number
WO 2004/032925 A1

(51) International Patent Classification⁷: **A61K 31/44**,
31/137, 31/704, 31/335, 31/4745, A61P 35/00

TN 38103 (US). **TRAXLER, Peter** [CH/CH]; Bündten-
ring 3, CH-4124 Schönenbuch (CH).

(21) International Application Number:
PCT/EP2003/011271

(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellec-
tual Property, CH-4002 Basel (CH).

(22) International Filing Date: 10 October 2003 (10.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/417,915 11 October 2002 (11.10.2002) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ,
TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except AT, US*): **NO-
VARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel
(CH).

(84) Designated States (*regional*): Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,
IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(71) Applicant (*for AT only*): **NOVARTIS PHARMA GMBH**
[AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(71) Applicant (*for all designated States except US*): **ST.
JUDES CHILDREN'S RESEARCH HOSPITAL**
[US/US]; 332 N. Lauderdale St., Memphis, TN 38103
(US).

Published:


- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **HOUGHTON, Pe-
ter, J.** [US/US]; 158 Harbor Town Boulevard, Memphis,

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: USE OF IMATINIB (GLIVEC, STI-571) TO INHIBIT BREAST CANCER RESISTANCE PROTEIN (BCRP)-MEDI-
ATED RESISTANCE TO THERAPEUTIC AGENTS



(I)

(57) Abstract: The present invention relates to the use of imatinib of the following formula (I) or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of a cancer that expresses breast cancer resistant protein (BCRP) in a human subject in need of such a treatment.